Lake Street Capital Has Lowered Expectations for Ekso Bionics (NASDAQ:EKSO) Stock Price

Ekso Bionics (NASDAQ:EKSO) had its price target lowered by Lake Street Capital from $2.50 to $2.00 in a research report report published on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock.

Other analysts also recently issued research reports about the stock. HC Wainwright decreased their price objective on shares of Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Tuesday. StockNews.com assumed coverage on Ekso Bionics in a report on Saturday, October 26th. They issued a “hold” rating on the stock.

Ekso Bionics Stock Performance

Shares of EKSO opened at $0.89 on Tuesday. Ekso Bionics has a one year low of $0.83 and a one year high of $3.13. The firm has a market capitalization of $19.51 million, a PE ratio of -1.36 and a beta of 1.45. The company has a 50-day simple moving average of $1.11 and a two-hundred day simple moving average of $1.15. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 1.77.

Ekso Bionics (NASDAQ:EKSO) last posted its earnings results on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The business had revenue of $4.13 million during the quarter, compared to the consensus estimate of $6.00 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. During the same period in the previous year, the business posted ($0.24) EPS. On average, analysts anticipate that Ekso Bionics will post -0.48 EPS for the current fiscal year.

Hedge Funds Weigh In On Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC increased its position in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 596,050 shares of the company’s stock after acquiring an additional 454,892 shares during the period. Kent Lake Capital LLC owned approximately 3.28% of Ekso Bionics worth $811,000 as of its most recent SEC filing. Institutional investors own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.